Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IPH5301 |
Synonyms | |
Therapy Description |
IPH5301 is a monoclonal antibody that binds to and inhibits soluble and membrane-bound CD73, thereby blocking synthesis of adenosine from AMP, which potentially leads to activation of T-lymphocytes and antitumor immune response (PMID: 31116985). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IPH5301 | IPH-5301|IPH 5301|IPH53|IPH 53 | CD73 Antibody 12 | IPH5301 is a monoclonal antibody that binds to and inhibits soluble and membrane-bound CD73, thereby blocking synthesis of adenosine from AMP, which potentially leads to activation of T-lymphocytes and antitumor immune response (PMID: 31116985). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |